HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.

ABSTRACT: Breast cancer in very young women (BCVY) defined as <35 years old, presents with different molecular biology than in older patients. High HDAC5 expression has been associated with poor prognosis in breast cancer (BC) tissue. We aimed to analyze HDAC5 expression in BCVY and older patients and their correlation with clinical features, also studying the potential of HDAC5 inhibition in BC cell lines. HDAC5 expression in 60 BCVY and 47 older cases were analyzed by qRT-PCR and correlated with clinical data. The effect of the HDAC5 inhibitor, LMK-235, was analyzed in BC cell lines from older and young patients. We performed time and dose dependence viability, migration, proliferation, and apoptosis assays. Our results correlate higher HDAC5 expression with worse prognosis in BCVY. However, we ob

SUBMITTER: Oltra SS 

PROVIDER: S-EPMC7072585 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature